Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.48 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.43 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7340113 | 1.00 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL4295210 | 1.00 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL7339574 | 1.00 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL10335706 | 1.00 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL4299442 | 1.00 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL4309898 | 1.00 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL2553275 | 1.00 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL15522266 | 1.00 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL2670678 | 1.00 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 | |
| SCHEMBL11108585 | 1.00 | DNM1 (0.48) | DNM1ZDHHC7LCKPPARDZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120177698-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | CEVC GREGOR (DE) | 2012-07-12 | — | — | US | disclosed |
| US-20090155235-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2009-06-18 | — | — | US | disclosed |
| US-7473432-B2 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery | IDEA AG (DE) | 2009-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177698-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | CUTA, ABCG2, ABCB11 | DNM1 4734/4885ZDHHC7 4866/4885LCK 2551/4885 |
| US-20090155235-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | CUTA, ABCG2, PIGS | DNM1 4871/4885ZDHHC7 4825/4885LCK 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.